ZFIN All Figures, Arslan <i>et al.</i>, 2022

Arslan et al., 2022

ZDB-PUB-220402-8
PMID:35361822
Figure 1
Figure 2
Figure 3
Figure 4

FIGURE SUMMARY

Title: Effect of non-repetitive linker on in vitro and in vivo properties of an anti-VEGF scFv
Authors: Arslan, M., Karadag, M., Onal, E., Gelinci, E., Cakan-Akdogan, G., Kalyoncu, S.
Source: Full text @ Sci. Rep.

Figure 1

(A) Schematic representation of designed L1 and L2 scFvs. (B) SDS-PAGE analysis of purified L1 and L2. Full image of the SDS-PAGE gel is provided in Supplementary Figure 1. (C) SEC chromatograms of L1 (blue) and L2 (orange) from SE-HPLC analysis.

Figure 2

Thermal melting temperatures of L1 and L2. Transition mid-points (T_m values) from fluorescent thermal melt assays were calculated by Hill equation fit. The assay was repeated 3 times.

Figure 3

Figure 4

In vivo angiogenesis inhibition by L1, L2 and bevacizumab. (A) Lateral view of subintestinal vessels (SIVs) in fli1:EGFP transgenic zebrafish larvae at 3 dpf. (B) PBS (negative control) (C) 27.5 μM bevacizumab (D) 55 μM L1, (E) 55 μM L2 were injected into yolk of 2 dpf fli1:EGFP transgenic zebrafish embryos. At 3 dpf, zebrafish SIVs were imaged by confocal microscopy. (F) Percentages of average SIV areas were quantified. The outcomes are expressed as AVG ± SD. n_PBS = 25, n_bevacizumab = 24, n_L1 = 24, n_L2 = 23. Statistical analysis was performed using one-tail t-test. Statistical results: n.s. p > 0.05, ****p < 0.0001.

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Sci. Rep.

Arslan et al., 2022 ZDB-PUB-220402-8 PMID:35361822

Effect of non-repetitive linker on in vitro and in vivo properties of an anti-VEGF scFv

Arslan et al., 2022

ZDB-PUB-220402-8
PMID:35361822